Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 276-282

  Reiche, Ines ^a   Westphal, Sabine ^a   Martens Lobenhoffer, Jens ^a   Trger, Uwe ^a   Luley, Claus ^a   Bode Bger, Stefanie M ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

dialysis patients; dose recommendation; extended release nicotinic acid; patients with CKD; pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ATORVASTATIN; DRUG METABOLITE; GLIMEPIRIDE; N(G),N(G) DIMETHYLARGININE; NICOTINAMIDE; NICOTINIC ACID; NICOTINURIC ACID; OMEPRAZOLE; PHENPROCOUMON; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DYSLIPIDEMIA; FEMALE; FLUSHING; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME;

AGED; CHRONIC DISEASE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; NIACIN; NIACINAMIDE; NICOTINIC ACIDS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 78650644199     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq344     Document Type: Article

References (21)

1. Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008; 153: 68-75
2. Pieper JA. Overview of niacin formulations: differences in pharma-cokinetics, efficacy, and safety. Am J Health Syst Pharm 2003; 60: S9-S14
3. Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacin (Niaspan): a long term study. Am J Cardiol 1998; 82: 74U-81U
4. Goldberg A, Alagona P Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85: 1100-1105
5. Insull W Jr, McGovern ME, Schrott H et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004; 164: 1121-1127
6. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998; 82: 29U-34U
7. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361: 2113-2122
8. Mrochek JE. Metabolic responses of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem 1976; 22: 1821-1827
9. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000; 86: 35L-40L
10. Pieper JA. Understanding niacin formulations. Am J Manag Care 2002; 8: S308-S314
11. Westphal S, Borucki K, Luley C et al. Treatment with Niacin lowers ADMA. Atherosclerosis 2006; 184: 448-450
12. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 2010; 47: 17-28
13. Pfuhl P, Karcher U, Haring N et al. Simultaneous determination of niacin, niacinamide and nicotinuric acid in human plasma. J Pharm Biomed Anal 2005; 36: 1045-1052
14. Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric di-methylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006 Mar; 52: 488-493
15. Menon RM, Adams MH, González MA et al. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 2007; 45: 448-454
16. Cayen MN. Disposition, metabolism and pharmacokinetics of antihy-perlipidemic agents in laboratory animals and men. Pharmacol Ther 1985; 29: 157-204
17. Stern RH. The role of nicotinic acid metabolites in flushing and hepatotoxicity. J Clin Lipidol 2007; 1: 191-193
18. Gaudineau C, Auclair K. Inhibition of human P450 enzymes by ni-cotinic acid and nicotinamide. Biochem Biophys Res Comm 2004; 317: 950-956
19. Cho K, Kim H, Rodriguez-Iturbe B et al. Niacin ameliorates oxi-dative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am J Physiol Renal Physiol 2009; 297: F106-F113
20. Grundy SM, Vega GL, McGovern ME et al. Diabetes Multicen-ter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568-1576
21. Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of nia-span, a controlled-release niacin, in patients with hypercholesterol-emia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996; 1: 195-202